CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,340 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01721837
NCT01721837N/ACompleted
CompareCT.gov

Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment

Boehringer Ingelheim·observational·Posted Nov 6, 2012·Updated Jul 31, 2014

In Brief

An observational study for Atrial Fibrillation. Completed, enrolled 4,340 participants across 1,616 sites.

Detailed Summary

Non-interventional, observational study of physicians' use of Dabigatran etexilate for stroke prevention in patients with atrial fibrillation and mild to moderate renal impairment

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesGermany
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 6, 2012
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 13.7 years ago